Primer: Fujian Haixi Pharmaceuticals (FHP HK) - Apr 2026
Fujian Haixi Pharmaceuticals is a commercial-stage pharmaceutical company in China with an integrated business model encompassing R&D,...
101 Views
HK: Cornerstone/Pre-IPO Lock-Up Expiries in April
There are 6 companies that listed in Oct where the lock-up for cornerstone investors ends in April. JST has a pre-IPO expiry too. The total lock-up...
888 Views
HSCI Index Rebalance Preview and Stock Connect (Mar 2026): Many Changes Following Huge IPO Quarter
There could be 74 changes for the HSCI in March. That could result in 64 changes to the Southbound Stock Connect list and also have implications...
1.5k Views
Hong Kong: IPO SPOTLIGHT - OVERVIEW 2025
Hong Kong is the top global destination for IPOs in 2025, with over HK $280 billion raised so far. Large scale A+H dual listings have surged this...
961 Views
Fujian Haixi Pharmaceuticals IPO: Expanding Portfolio Augurs Well for Sustainable Growth
Haixi Pharmaceuticals is offering 11.5M H shares at HK$86.40 per share for its HK IPO to raise up to HK$994M. IPO proceeds will fund R&D of...
669 Views